Reply to the Letter to the Editor: Why Did the "Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists" Differ From the Previous Randomized Controlled Study?